---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-099355"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:51:03.707431+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cullinan reports $439M cash, $219.9M net loss; CLN-978 data and zipalertinib NDA on track

## Summary
- Cash and investments of $439.0M as of Dec 31, 2025; runway into 2029.
- Net loss of $50.7M in Q4 2025 ($219.9M full year), vs $47.6M in Q4 2024.
- Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA in Q3 2026.
- Zipalertinib rolling NDA submission completed; REZILIENT3 frontline study enrollment completed, top-line results by year-end 2026.
- Cullinan eligible for $30M upon 2L U.S. approval, up to $100M upon 1L, plus 50/50 profit share.

## SEC filing metadata
- accession: 0001193125-26-099355
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312526099355/0001193125-26-099355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312526099355/cgem-20260310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-099355
- JSON: https://secwatch.observer/filing/0001193125-26-099355.json
- Plain text: https://secwatch.observer/filing/0001193125-26-099355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.